Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7760 · 2 trials · 2 indications
To evaluate the safety of AZD7760 administered as a single IV Dose A or Dose B in healthy Japanese adult participants.
To evaluate the safety of AZD7760 administered as a single IV Dose A or Dose B in healthy Japanese adult participants.
To evaluate the safety of AZD7760 administered as a single intravenous (IV) Dose A, B, or C.
To evaluate the safety of AZD7760 administered as a single IV Dose A, B, or C.
To evaluate the safety of AZD7760 compared with placebo as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (AZD7760 Dose A) | EXPERIMENTAL | Participants receive an IV infusion of AZD7760 Dose A on Day 1. |
| Cohort 2 (AZD7760 Dose B) | EXPERIMENTAL | Participants receive an IV infusion of AZD7760 Dose B on Day 1. |
| Pooled Placebo | PLACEBO_COMPARATOR | Participants receive an IV infusion of matching placebo on Day 1. |
| Phase I: AZD7760 Dose A | EXPERIMENTAL | Participants will receive a single dose of AZD7760 Dose A intravenously on Day 1. |
| Phase I: AZD7760 Dose B | EXPERIMENTAL | Participants will receive a single dose of AZD7760 Dose B intravenously on Day 1. |
| Phase I: AZD7760 Dose C | EXPERIMENTAL | Participants will receive a single dose of AZD7760 Dose C intravenously on Day 1. |
| Phase I: Placebo | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo on Day 1. |
| Phase IIa: AZD7760 Dose D and Placebo | EXPERIMENTAL | Participants will receive AZD7760 Dose D and placebo on Day 1 on Day 91. |
| Phase IIa: AZD7760 Dose E | EXPERIMENTAL | Participants will receive AZD7760 Dose E on Day 1 and Day 91. |
| Phase IIa: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo on Day 1 and on Day 91. |
| Name | Type | Description |
|---|---|---|
| AZD7760 | DRUG | Participants will receive AZD7760 via IV infusion. |
| Placebo | OTHER | Participants will receive matching placebo via IV infusion. |
Inclusion Criteria: * Body weight ≥ 45 kg and ≤ 110 kg and BMI within the range of ≥ 18.0 to ≤ 30.0 kg/m2 (inclusive) at screening. * Healthy Japanese participants with no clinically significant concomitant diseases or medications. Exclusion Criteria: * Known hypersensitivity to any component of ...
AZD7760 is an investigational small molecule developed by AstraZeneca PLC for infectious disease, specifically Staphylococcus aureus and Staphylococcus aureus bloodstream infection. It is in Phase 1 clinical development and has not been approved. The program includes studies in healthy adults and in patients with end-stage kidney disease on hemodialysis with a central venous catheter.
AZD7760 is being studied for Staphylococcus aureus and Staphylococcus aureus bloodstream infection. It is an investigational therapy and is not approved for any use. Clinical evaluation to date has focused on safety and pharmacokinetics in healthy volunteers and in adults with end-stage kidney disease on hemodialysis with a central venous catheter.
AZD7760 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program evaluating the compound in Staphylococcus aureus and Staphylococcus aureus bloodstream infection.
AZD7760 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory authority. The Phase 1 program includes a study in healthy Japanese adults and a study in healthy adults and adults with end-stage kidney disease on hemodialysis with a central venous catheter.
AZD7760 is being evaluated in two registered trials. NCT07612813 is a Phase 1 study of safety and pharmacokinetics in healthy Japanese adults, enrolling 18 participants in Japan. NCT06749457 is a Phase 1 and Phase 2a study in healthy adults and adults with end-stage kidney disease on hemodialysis with a central venous catheter, enrolling 244 participants in the United States.
Yes. The AZD7760 clinical program is randomized, double blind, and placebo controlled. The trials are designed to evaluate safety and pharmacokinetics rather than efficacy endpoints, and both registered studies are currently active but not recruiting. Enrollment across the program totals 244 participants, with no biomarker-based patient selection.